Orphan Drug Development: Opportunities and Challenges from a Midsized to Large Company Perspective Rosann ReinhartKrysten Madrzjewski Regulatory Affairs 30 December 2010 Pages: 101 - 109
Development of Clinical Trial Agreement Principles Michelle MoldofskyKaren ArtsArthur S. Slutsky Regulatory Affairs 30 December 2010 Pages: 111 - 117
The Way Forward in Package Insert User Tests from a CRO’s Perspective Joerg Fuchs Regulatory Affairs 30 December 2010 Pages: 119 - 129
Change in Student Perception after a Pharmaceutical Industry Advanced Pharmacy Practice Experience Christopher M. MarroneGuy C. Ruble Regulatory Affairs 30 December 2010 Pages: 131 - 136
Coping with the Regulatory Realities of Follow-on Biologics and the Nuances of US and European Regulations Joel I. FolkRoss A. Davidson Regulatory Affairs 30 December 2010 Pages: 137 - 145
Determining an Adaptive Exclusion Procedure following Discovery of an Association between the Whole Genome and Adverse Drug Reactions Ting-Li SuHelene ThygesenClive Bowman Biostatistics 30 December 2010 Pages: 147 - 157
Exact Critical Values for Farrington-Manning Noninferiority Exact Test David Sotres-RamosFelix Almendra-AraoCecilia Ramírez-Figueroa Biostatistics 30 December 2010 Pages: 159 - 164
Noninferiority Margin for Clinical Trials of Antibacterial Drugs for Nosocomial Pneumonia Alfred SorbelloScott KomoThamban Valappil Biostatistics 30 December 2010 Pages: 165 - 176
E-Business in the Regulation of Medicines in Serbia Tatjana StojadinovicVesela RadonjicBozidar Radenkovic Pharmacoeconomics 30 December 2010 Pages: 177 - 187
Do Drug Price Adjustment Policies Work? The Impact of Physician Financial Incentive Plans on the Implementation of Drug Cost Containment Mechanisms Hsuan-Lien ChuShuen-Zen LiuJames C. Romeis Pharmacoeconomics 30 December 2010 Pages: 189 - 198
2010 EuroMeeting Student Poster Abstracts Springer 2010 Euromeeting 30 December 2010 Pages: 199 - 204